2026-2032 年食品疫苗市場（按類型、應用和地區）

食品疫苗市場評估-2026-2032

替代疫苗接種方法的需求日益成長，尤其是在發展中地區，這推動了人們對可食用疫苗的興趣。感染疾病的日益普及以及人們對預防醫學日益成長的興趣，正在推動該領域的研究投資和創新。 2023年，可食用疫苗的需求將超過83.5億美元，到2032年將達到129.1億美元。

此外，植物生物技術的進步使得透過基因改造作物生產疫苗成為可能，也使得食用疫苗的生產更加可行。食用疫苗的成本效益、易儲存和易於運輸特性進一步推動了市場擴張，因為它們解決了全球疫苗接種工作中的一個關鍵挑戰。這些因素正在推動各行各業對食用疫苗的使用日益增多，預計2026年至2032年的複合年成長率將達到6.18%。

食品疫苗市場定義/概述

食品疫苗是指基因改造作物或植物，其產生的抗原在攝取後會刺激免疫反應，從而提供一種簡單、無需針頭的疫苗接種方法。其主要應用包括控制B肝、霍亂和狂犬病等感染疾病，而傳統的疫苗接種方式在後勤和取得方面存在障礙。未來，食品疫苗有望成為一種廣泛且經濟有效的疫苗接種方式，尤其是在資源匱乏的地區，因為它們可以減少對低溫運輸的依賴並降低生產成本。植物生物技術的發展和人們對預防醫學日益成長的興趣預計將推動未來的發展，使食品疫苗成為全球公共衛生舉措中一個極具潛力的工具。

預防保健意識的不斷增強會推動食品疫苗市場的發展嗎？

預防保健意識的提升是食品疫苗市場的主要驅動力。隨著人們預防性衛生意識的增強，人們開始採取積極主動的措施來對抗疾病，這導致人們對食品疫苗等創新疫苗解決方案的興趣日益濃厚。世界衛生組織 (WHO) 指出，每年約有 150 萬人死於疫苗可預防的疾病，凸顯了製定有效疫苗接種策略的必要性。美國疾病管制與預防中心 (CDC) 報告稱，隨著疫苗接種意識的不斷提高，兒童脊髓灰質炎和麻疹等疾病的疫苗接種率已接近 95%。

這種對可及性和非侵入性疫苗解決方案的需求，尤其是在醫療基礎設施有限的地區，與可食用疫苗的優勢相得益彰，進一步刺激了市場發展。此外，可食用疫苗為疫苗接種中的一個關鍵物流挑戰提供了解決方案。與傳統疫苗不同，它們無需冷藏，尤其適用於缺乏穩定低溫運輸基礎設施的地區。根據聯合國的報告，超過30%的低收入國家面臨低溫運輸短缺，影響了有效免疫接種的發展。食品疫苗可以幫助應對這些挑戰，因為它們可以在當地以更少的資源生產和分銷。

高成本和高可近性會阻礙食品疫苗市場的成長嗎？

高成本和供應不足可能會阻礙可食用疫苗市場的成長。可食用疫苗的開發需要先進的基因工程、嚴格的臨床試驗和監管部門的核准，所有這些都會增加生產成本。這些費用可能會限制人們的可負擔性，尤其是在中低收入國家，因為這些國家的傳統疫苗通常由政府計畫和國際組織津貼。如此高成本結構可能會減緩疫苗的普及速度，尤其是在資源有限的地區。

此外，由於並非所有地方都具備大規模種植和推廣基改作物的基礎設施，食品的可及性仍然是一個問題。在歐洲等地區，嚴格的作物改造法律規範也構成了障礙，可能會限制食品疫苗的推廣。因此，儘管食品疫苗具有良好的前景，但其高昂的成本和有限的供應對其廣泛應用構成了重大挑戰。

目錄

第1章：全球食品疫苗市場簡介

• 市場概覽
• 研究範圍
• 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

• 資料探勘
• 驗證
• 第一手資料
• 資料來源列表

第4章 食品疫苗的全球市場展望

• 概述
• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 波特五力模型
• 價值鏈分析

第5章全球食品疫苗市場（按應用）

• 概述
• 家畜
• 醫療保健

6. 全球食品疫苗市場（按類型）

• 概述
• 去活化疫苗
• 其他

7. 全球食品疫苗市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

第8章全球食品疫苗市場競爭格局

• 概述
• 各公司市場排名
• 主要發展策略

第9章 公司簡介

• GlaxoSmithKline
• Sanofi SA
• Merck & Co., Inc.
• Ceva
• Santa Cruz Animal Health
• Merial

第10章 重大進展

• 產品發布/開發
• 合併與收購
• 業務擴展
• 夥伴關係與合作

第11章 附錄

• 相關調查

Edible Vaccine Market Valuation - 2026-2032

The rising demand for alternative vaccination methods, particularly in developing regions, is propelling interest in edible vaccines as they offer an easier, needle-free delivery mechanism that enhances accessibility and compliance. Increasing prevalence of infectious diseases and growing focus on preventive healthcare are encouraging research investments and innovation in this field. The need for edible vaccine is surpassing USD 8.35 Billion in 2023 and reaching USD 12.91 Billion by 2032.

Additionally, advances in plant biotechnology, which enable the genetic modification of crops to produce vaccines, have strengthened the feasibility of edible vaccines. The cost-effectiveness, ease of storage, and transport of edible vaccines further fuel market expansion as these factors address critical challenges in global immunization efforts. These factors contribute to the increasing use of edible vaccine in a variety of industries is expected to grow at a CAGR of 6.18% about from 2026 to 2032.

Edible Vaccine Market: Definition/ Overview

Edible vaccines are genetically engineered crops or plants that produce antigens, stimulating an immune response when consumed, offering a needle-free, easily administered vaccination method. Their primary applications include combating infectious diseases like hepatitis B, cholera, and rabies, where traditional vaccination faces logistical or accessibility barriers. Looking ahead, edible vaccines hold potential for widespread, cost-effective immunization, especially in low-resource settings, as they reduce cold-chain dependency and production costs. Advances in plant biotechnology and growing interest in preventive health are expected to drive future developments, making edible vaccines a promising tool for global public health initiatives.

Will Growing Awareness of Preventive Healthcare is Propelling the Edible Vaccine Market?

Growing awareness of preventive healthcare is significantly propelling the Edible Vaccine Market. As populations become increasingly conscious of preventive health, there is a shift towards proactive measures in combating diseases, boosting interest in innovative vaccination solutions like edible vaccines. The World Health Organization (WHO) notes that vaccine-preventable diseases cause approximately 1.5 million deaths each year, emphasizing the need for effective immunization strategies. In the United States, the Centers for Disease Control and Prevention (CDC) reports a rising trend in vaccination awareness, with vaccination coverage among children reaching nearly 95% for diseases like polio and measles, showcasing the population's inclination toward preventive healthcare.

This demand for accessible, non-invasive vaccine solutions, particularly in regions with limited healthcare infrastructure, aligns with the benefits of edible vaccines, further fueling the market. Additionally, edible vaccines offer solutions to critical logistical challenges in vaccination. Unlike traditional vaccines, they don't require refrigeration, making them especially suitable for areas without consistent cold-chain infrastructure. According to a United Nations report, over 30% of low-income countries face cold chain shortages, which impact effective immunization coverage. Edible vaccines can help address these challenges, as they can be produced and distributed locally with fewer resources.

Will High Costs and Accessibility Hamper the Growth of the Edible Vaccine Market?

High costs and accessibility challenges could hamper the growth of the Edible Vaccine Market. Developing edible vaccines requires advanced genetic engineering, rigorous clinical trials, and regulatory approvals, all of which add to production costs. These expenses may limit affordability, especially in low- and middle-income countries where traditional vaccines are often subsidized by government programs or international organizations. This high-cost structure could slow adoption rates, particularly in regions where funding is limited.

Moreover, accessibility remains a concern as infrastructure for large-scale cultivation and distribution of genetically engineered crops may not be available everywhere. Strict regulatory frameworks governing genetically modified organisms (GMOs) in regions like Europe also present obstacles, potentially restricting edible vaccine deployment. As a result, while edible vaccines offer promising benefits, high costs and accessibility limitations pose significant challenges to their widespread adoption.

Category-Wise Acumens

Will Widespread Usage for Inactivated Vaccine Boost the Edible Vaccine Market?

The widespread usage of inactivated vaccines can indirectly boost the Edible Vaccine Market. Inactivated vaccines are well-regarded for their safety and effectiveness, fostering trust in vaccine-based preventive healthcare. This acceptance creates a favorable environment for innovative vaccines like edible vaccines, as the public becomes more open to varied vaccination methods. As awareness of different vaccine types grows, so does the interest in more accessible, needle-free alternatives, which could drive adoption of edible vaccines, especially in communities with high demand for convenient immunization options.

Furthermore, as inactivated vaccines require careful storage and distribution, edible vaccines offer an appealing alternative in areas where cold-chain logistics are challenging. Since edible vaccines can be produced in plants, they eliminate the need for cold storage and complex distribution, addressing critical barriers associated with inactivated vaccines in low-resource settings. This added advantage could position edible vaccines as a complementary solution, further enhancing the market's growth potential.

The "Others" segment, which includes newer vaccine technologies like mRNA and viral vector vaccines, is the fastest-growing.

Will Comprehensive Ability to Provide Medical Care Fuel the Edible Vaccine Market?

The comprehensive ability of edible vaccines to enhance medical care can fuel market growth. Edible vaccines offer a promising, needle-free alternative to traditional vaccines, making immunization more accessible, especially in regions with limited healthcare infrastructure. This ability to simplify vaccine administration aligns with public health goals for increased vaccination coverage, particularly in areas where medical resources and trained personnel are scarce.

Additionally, edible vaccines reduce logistical challenges associated with cold-chain storage and distribution. As they can be produced and stored with minimal refrigeration needs, edible vaccines lower costs and improve reach in remote and underserved areas. This ease of distribution and storage supports broader healthcare initiatives, making edible vaccines an attractive option to expand medical care capabilities globally, further driving their market potential.

The Livestock segment is the fastest-growing, fueled by increasing demand for efficient, cost-effective solutions to manage animal diseases in agriculture.

Country/Region-wise

Will Advanced Healthcare Infrastructure in North America Drive the Expansion of The Edible Vaccine Market?

The advanced healthcare infrastructure in North America is likely to drive the expansion of the Edible Vaccine Market. With highly developed research facilities, the region is well-positioned to support innovation in vaccine delivery systems like edible vaccines, addressing the need for easier, needle-free alternatives. The United States, in particular, invests significantly in healthcare, with federal research funding for the National Institutes of Health (NIH) reaching approximately $47.5 billion in 2022, part of which supports vaccine research and development. This robust investment landscape accelerates breakthroughs in biotechnology, supporting edible vaccine advancements.

Furthermore, high vaccination rates and supportive regulatory frameworks in North America create a favorable environment for introducing novel vaccine types. For example, in 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that approximately 72% of the population had received full COVID-19 vaccinations, showing widespread vaccine adoption and an openness to innovative health solutions. As demand for effective, accessible, and affordable vaccination options grows, edible vaccines are positioned to benefit from the region's sophisticated healthcare infrastructure and regulatory support, potentially leading to their expanded use in public health initiatives.

Will Rapid Economic Growth in Asia Pacific Propel the Edible Vaccine Market?

Rapid economic growth in the Asia-Pacific region is likely to propel the Edible Vaccine Market, primarily due to increased investment in healthcare infrastructure and a heightened focus on preventive health measures. As nations such as China and India continue to experience robust economic expansion, the demand for innovative healthcare solutions, including edible vaccines, is expected to rise significantly. According to the Asian Development Bank, the region's economy is projected to grow by approximately 5.5% in 2024, which will likely lead to increased government spending on health initiatives and improved access to vaccination programs.

Furthermore, the Asia-Pacific region faces a high burden of infectious diseases, which underscores the need for accessible vaccination solutions. The World Health Organization reported that vaccine-preventable diseases caused over 1.5 million deaths annually in low- and middle-income countries, many of which are located in this region. As governments aim to enhance immunization coverage, edible vaccines offer a viable alternative to traditional methods, facilitating easier distribution and administration. The combination of economic growth and an urgent health mandate creates a favorable environment for the Edible Vaccine Market to thrive in the Asia-Pacific region.

Competitive Landscape

The competitive landscape of the Edible Vaccine Market is characterized by rapid technological advancements and increasing innovation in diagnostic tools. Companies are focusing on developing more accurate, non-invasive, and user-friendly testing solutions to meet the growing demand for personalized and preventive healthcare. Strategic collaborations, mergers, and acquisitions are also common as firms aim to enhance their market presence and expand their product offerings.

Some of the prominent players operating in the Edible Vaccine Market include:

GlaxoSmithKline, Sanofi S.A., Merck & Co., Inc., Ceva, Santa Cruz Animal Health, Merial.

Latest Developments

In August 2024 A research team at the University of California developed an innovative oral vaccine using genetically modified edible plants. This new approach allows for easy administration without needles, potentially increasing vaccination rates. Early studies showed promising immune responses in animal models, indicating that this method could revolutionize how vaccines are delivered, particularly in underserved regions.

In July 2024 Syngenta announced a partnership with BioNTech to explore the development of edible vaccines using genetically engineered crops. This collaboration aims to leverage BioNTech's mRNA technology to create plants that can produce antigens for various diseases. The initiative could significantly reduce production costs and facilitate wider distribution of vaccines in developing countries.

In June 2024 the Food and Drug Administration (FDA) approved the first edible vaccine for rotavirus, developed by a biotechnology firm in collaboration with agricultural scientists. This landmark decision paves the way for future approvals of edible vaccines, highlighting a growing acceptance of plant-based vaccine technology. The vaccine is expected to be available in various food products, making it more accessible, especially for children in low-income countries.

Edible Vaccine Market, By Category

• Type:
• Inactivated Vaccines
• Others
• Application:
• Livestock
• Medical Care
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL EDIBLE VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL EDIBLE VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL EDIBLE VACCINE MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Livestock
• 5.3 Medical Care

6 GLOBAL EDIBLE VACCINE MARKET, BY TYPE

• 6.1 Overview
• 6.2 Inactivated Vaccines
• 6.3 Others

7 GLOBAL EDIBLE VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL EDIBLE VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Sanofi S.A.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Merck & Co., Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Ceva
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Santa Cruz Animal Health
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Merial
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research